435930 Sigma-AldrichLIM Kinase Inhibitor I, LIMKi 3 - Calbiochem
LIM Kinase Inhibitor I, LIMKi 3, CAS 1338247-35-0, is a cell-permeable, potent inhibitor of LIM kinase (IC50 = 7 & 8 nM against LIMK1 & LIMK2, respectively). Reduces MDA-MB-231 tumor cell invasion.
More>> LIM Kinase Inhibitor I, LIMKi 3, CAS 1338247-35-0, is a cell-permeable, potent inhibitor of LIM kinase (IC50 = 7 & 8 nM against LIMK1 & LIMK2, respectively). Reduces MDA-MB-231 tumor cell invasion. Less<<LIM Kinase Inhibitor I, LIMKi 3 - Calbiochem MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
同义词: N-(5-(1-(2,6-Dichlorophenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl)thiazol-2-yl)isobutyramide
Recommended Products
概述
Replacement Information |
---|
重要规格表
CAS # | Empirical Formula |
---|---|
1338247-35-0 | C₁₇H₁₄Cl₂F₂N₄OS |
价格及供货情况
产品目录编号 | 库存情况 | 包装 | 数量 / 包装 | 价格 | 数量 | |
---|---|---|---|---|---|---|
435930-10MGCN |
|
玻璃瓶 | 10 mg |
|
— |
References | |
---|---|
References | Scott, R.W., et al. 2010. J. Cell. Biol. 191, 169. Ross-Macdonald, P., et al. 2008. Mol. Cancer Ther. 7, 3490. |
Product Information | |
---|---|
CAS number | 1338247-35-0 |
Form | Beige powder |
Hill Formula | C₁₇H₁₄Cl₂F₂N₄OS |
Reversible | Y |
Structure formula Image | |
Quality Level | MQ100 |
Physicochemical Information | |
---|---|
Cell permeable | Y |
Dimensions |
---|
Materials Information |
---|
Toxicological Information |
---|
Safety Information according to GHS |
---|
Safety Information |
---|
Product Usage Statements |
---|
Packaging Information | |
---|---|
Packaged under inert gas | Packaged under inert gas |
Transport Information |
---|
Supplemental Information |
---|
Specifications |
---|
Global Trade Item Number | |
---|---|
产品目录编号 | GTIN |
435930-10MGCN | 04055977210330 |
Documentation
LIM Kinase Inhibitor I, LIMKi 3 - Calbiochem MSDS
职位 |
---|
LIM Kinase Inhibitor I, LIMKi 3 - Calbiochem 分析证书
标题 | 批号 |
---|---|
435930 |
参考
参考信息概述 |
---|
Scott, R.W., et al. 2010. J. Cell. Biol. 191, 169. Ross-Macdonald, P., et al. 2008. Mol. Cancer Ther. 7, 3490. |